Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Participants who qualify will receive lenalidomide daily on days 1-21 of every 28 day cycle.
Treatment will continue for up to 52 weeks or until disease progression; participants who
achieve a complete response (CR) will receive an additional 2 cycles of treatment prior to
discontinuation. Participants will be followed for progression free survival following
discontinuation from the treatment phase